Administration of aggregated beta-amyloid peptide (25-35) induces changes in long-term potentiation in the hippocampus in vivo

Neurosci Behav Physiol. 2003 Feb;33(2):95-8. doi: 10.1023/a:1021761310435.

Abstract

Intracereroventricular administration of aggregated beta-amyloid protein fragment (25-35) (7.5 nmol/ventricle) was followed one month later by significant changes in the dynamics of long-term potentiation in the hippocampus in vivo, expressed as powerful and stable increases in the amplitude of evoked potentials. This phenomenon may be associated with oxidative stress in the hippocampus, which has previously been demonstrated in this model, and, thus, with disturbances in ion homeostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / pharmacology*
  • Animals
  • Hippocampus / drug effects*
  • Hippocampus / physiology
  • Long-Term Potentiation / drug effects*
  • Male
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Wistar

Substances

  • Amyloid beta-Peptides
  • Peptide Fragments
  • amyloid beta-protein (25-35)